Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure

Area of Science:

• Cardiology
• Epigenetics
• Pharmacology

Background:

• Histone deacetylases (HDACs) are epigenetic regulators known to mitigate cardiac hypertrophy and fibrosis.
• The precise mechanisms behind the antifibrotic effects of HDAC inhibitors require further elucidation.
• This study aimed to assess the impact of an HDAC inhibitor on systolic heart failure (HF) and explore underlying mechanisms.

Purpose of the Study:

• To evaluate the therapeutic effects of a novel HDAC inhibitor, MPT0E014, on systolic heart failure (HF) in a rat model.
• To investigate the potential mechanisms by which MPT0E014 exerts its antifibrotic and cardioprotective effects.

Main Methods:

• Induction of HF in rats using isoproterenol, followed by administration of MPT0E014.
• Assessment of cardiac function and structure using echocardiography and histology.
• Quantification of key proteins (ANP, AT1R, TGF-β, CaMKIIδ) via Western blot.
• In vitro studies on primary cardiac fibroblasts to assess migration and proliferation.

Main Results:

• MPT0E014 treatment significantly improved cardiac contractility (fraction shortening) and reduced cardiac dimensions in HF rats.
• MPT0E014 administration led to decreased levels of ANP, cardiac fibrosis, AT1R, TGF-β, and CaMKIIδ.
• In vitro, MPT0E014 (1 μM) inhibited cardiac fibroblast migration and proliferation, and reduced AT1R and TGF-β expression at both 0.1 and 1 μM concentrations.

Conclusions:

• MPT0E014 demonstrates efficacy in improving cardiac contractility and attenuating structural remodeling in a rat model of dilated cardiomyopathy.
• The observed beneficial effects are likely attributed to the direct antifibrotic activity of MPT0E014, potentially via modulation of AT1R and TGF-β signaling pathways.